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Abstract
Prostate cancer remains a leading cause of death in men despite increased capacity to diagnose at
earlier stages. After prostate cancer has become hormone independent, which often occurs after
hormonal ablation therapies, it is difficult to effectively treat. Prostate cancer may arise from
mutations and dysregulation of various genes involved in regulation signal transduction (e.g., PTEN,
Akt, etc.,) and the cell cycle (e.g., p53, p21Cip1, p27Kip1, Rb, etc.,). This review focuses on the
aberrant interactions of signal transduction and cell cycle genes products and how they can contribute
to prostate cancer and alter therapeutic effectiveness.
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Prostate Cancer: The Most Prevelant Cancer in Men
Due to increasingly reliable methods of detection, carcinoma of the prostate (CaP) has become
the most commonly-diagnosed cancer in men in the United States. This year alone,
approximately 230,000 American males will be diagnosed with CaP and nearly 30,000 will
die from this deadly disease (source: American Cancer Society). Despite increased public
awareness and improved procedures for surgical intervention of CaP, there remains no effective
cure for patients with advanced disease. Moreover, treatment regimens are limited to radiation
and/or chemotherapy, which primarily provide palliative benefits while offering little in the
form of increased life expectancy. Consequently, studies designed to better understand the
etiology of this disease should lead to more effective treatments in the clinic.
Over the past decade, scientists have discovered that early detection drastically reduces death
due to CaP. Consequently, during this time a vast majority of the research that has focused on
identifying prognostic indicators of advanced disease versus those markers associated with
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earlier stages of CaP. However, much less has been discovered during this time regarding the
development and natural progression of the disease.
There are a number of factors that have been correlated to the development of CaP including
age (increased diagnosis after 60 years; 1 in 7 men), environmental factors (race, diet, etc.,),
familial inheritance (10% of CaP are associated with hereditary factors), and steroid hormone
signaling (decreased reliance upon testosterone), among others.1 While each of these factors
appears to be intimately associated with the development of disease, one must comprehend
what occurs on the molecular level to develop better treatment strategies and possible cures.
2,3
The prostate gland surrounds the urethra at the base of the bladder and functions by producing
secretory proteins for semen. There are at least three different cell types that comprise the
prostatic epithelium: (1) secretory luminal epithelial cells—a well-differentiated androgen-
dependent cell that functions to secrete prostatic proteins, (2) basal cells—situated between
the secretory luminal cell layer and the underlying basement membrane, (3) neuroendocrine
cells—androgen-independent cells that are located in the same stratum as the basal cells and
are believed to provide paracrine signals to the adjacent luminal cells, and (4) prostate stem
cells—not proven yet, but anticipated to exist.
Prostatic intraepithelial neoplasia (PIN) are preneoplastic lesions that precede the advent of
prostate cancer. PIN lesions are characterized by loss of basal cells and invasion of luminal
cells into the periphery. The exact causes surrounding the onset of PIN are unknown; however,
a prominent theory is that loss of particular chromosomes may be major contributory factors
in this process. Chromosomes 8p, 10q and 13q are all frequently lost in CaP; there are a number
of important tumor suppressor genes found on these chromosomes including NKX3.1,4-6
PTEN/MMAC1,7-12 and Rb,13-16 respectively.
Central Role of PI3K/PTEN/Akt/mTOR Pathway in Prostate Cancer
Chromosome 10q is frequently lost (50-80%) in prostatic lesions. PTEN is located within this
locus (10q23) and is a well-known negative regulator of the PI3K/Akt signal transduction
cascade. The PI3K/Akt signaling pathway is known for its role in mediating cell survival, as
well as cell cycle progression and neoplastic transformation.17 Consequently, it would stand
to reason that mutation of PTEN would initiate heightened activation of this cascade, which
could then confer a number of cancer-like properties to the cell. Many of these, particularly
cellular survival, are hallmark features of CaP tumor cells.
Phosphatidylinositol-3-kinase (PI3K) is a heterodimeric protein with an 85-kDa regulatory
subunit and a 110-kDacatalytic subunit. PI3K serves to phosphorylate a series of membrane
phospholipids including PtdIns(4)P and PtdIns(4,5)P2, catalyzing the transfer of ATP-derived
phosphate to the D-3 position of the inositol ring of membrane phosphoinositides, thereby
forming the second messenger lipids PtdIns(3,4)P2 and PtdIns(3,4,5)P3. Most often, PI3K is
activated via the binding of a ligand to its cognate receptor, whereby p85 associates with
phosphorylated tyrosine residues on the receptor via an SH2 (Src-homology 2) domain. After
association with the receptor, the p110 catalytic subunit then transfers phosphate groups to the
aforementioned membrane phospholipids. It is these lipids, specifically PtdIns(3,4,5)P3, that
attract a series of kinases to the plasma membrane thereby initiating the signaling cascade.18
An overview of the PI3K/PTEN/Akt/mTOR pathway is presented in Figure 1.
Downstream of PI3K is the primary effector molecule of the PI3K signaling cascade, Akt/PKB
(protein kinase B). Akt was originally discovered as the cellular homologue of the transforming
retrovirus AKT8 and as a kinase with properties similar to protein kinases A and C.19,20 Akt
contains an amino-terminal pleckstrin homology (PH) domain that serves to target the protein
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to the membrane for activation.21-23 Within its central region, Akt has a large kinase domain
and is flanked on the carboxy-terminus by hydrophobic and proline-rich regions.24,25 Akt is
activated via phosphorylation of two residues: T308, S473. While it is generally agreed upon
that maximal activation of Akt requires phosphorylation of both of these residues, there are
conflicting reports regarding the relative importance of S473 and T308 for initial activation of
Akt. It was originally thought that either of these residues could be phosphorylated to initiate
Akt activity and that phosphorylation of one residue was not necessary for phosphorylation of
the other to occur.26 More recent evidence suggests that phosphorylation of T308 is absolutely
essential for phosphorylation of S473.27,28 Each of these studies was carried out in the
HEK293 cell line, which further compounds the issue because the differences cannot be
attributed to cell type.
The phosphotidylinositide-dependent kinases (PDKs) are responsible for activation of Akt.
PDK1 is the kinase responsible for phosphorylation of T308,29 while the actual kinase that
phosphorylates S473 (PDK2) remains controversial. Some report that phosphorylation of T308
triggers autophosphorylation of S473,30 while others hypothesize that PDK2 is the integrin-
linked kinase (ILK).31 However, it is now believed that ILK may facilitate phosphor-ylation
of S473 indirectly, perhaps by acting as a scaffolding protein.32 Akt can also be phosphorylated
by the mTOR complex called Rictor.33 Phosphorylation of Akt is complicated as it can be
phosphorylated by a complex which lies downstream of itself. Moreover, it can be
dephosphorylated by p70S6K which also lies downstream of Akt.34 Once activated on either/
both of these residues, Akt leaves the cell membrane to phosphorylate intracellular substrates.
After activation, Akt is able to translocate to the nucleus35 where it affects the activity of a
number of transcriptional regulators. Cyclic-AMP response element binding protein (CREB),
36 E2F,37-39 NFκB (via Iκ-K),40,41 and the forkhead transcription factors42-50 are all either
direct or indirect substrates of Akt and each can promote either cellular proliferation or survival.
Aside from transcription factors, Akt is able to target a number of other molecules to affect the
survival state of the cell including caspase-9,51 the pro-apoptotic molecule BAD,52,53 and
glycogen-synthase kinase-3β (GSK-3β).54 When these targets are phosphorylated by Akt, they
may either be activated or inactivated but the end result is to promote survival of the cell.
Negative regulation of the PI3K pathway is primarily accomplished through the action of the
PTEN tumor suppressor protein. PTEN encodes a lipid and protein phosphatase whose primary
lipid substrate is PtdIns(3,4,5)P3. The protein substrate(s) of PTEN are more varied, including
focal adhesion kinase (FAK), the Shc exchange protein and the transcriptional regulators
ETS-2,55 and Sp1.56 PTEN also may negatively regulate the activation of the platelet-derived
growth factor (PDGF) receptor.57
PTEN has four primary structural domains. On the amino terminus is the lipid and protein
phosphatase domain, which is flanked adjacent to the C2 domain that is responsible for lipid
binding and membrane localization. Next are two PEST domains which regulate protein
stability. Lastly, PTEN has a PDZ domain, which helps facilitate protein-protein interactions.
Mutations within the phosphatase domain have been reported to nullify the endogenous
function of PTEN.58-60
As previously mentioned, loss of PTEN function in advanced CaP is quite common (50-80%
of patients).61,62 As a consequence, this results in an overabundance of lipid second
messengers [PtdIns(3,4,5)P3], which can cause constitutive activation of PH domain-
containing proteins including Akt. It is for this reason that Akt is found to be highly-activated
in advanced cases of CaP.63,64 Aberrant Akt activation is able to elicit the pro-survival
properties observed in CaP cells through a number of mechanisms, described hereafter. Hence
inhibiting Akt or restoring PTEN activities are potential therapeutic targets in prostate cancer.
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p27Kip1 is a central mediator of cell cycle progression whose role as a cyclin-dependent kinase
(CDK) inhibitor is lost in many cases of advanced CaPs.65-69 The role of p27Kip1 in preventing
prostatic disease is bolstered by evidence which shows that p27Kip1-null mice quickly develop
prostatic hyperplasia.70 Akt appears to affect p27Kip1 expression via the intermediate
molecule, FKHR. FKHR (FOXO1) is a member of the forkhead/FoxO family of transcription
factors, which are known to stimulate transcription of p27Kip1.71 Upon activation, Akt
phosphorylates FKHR causing its inactivation and subsequent downregulation of p27Kip1.
Further evidence has shown that constitutively-active Akt may be able to decrease the half-life
of p27Kip1 as well.72,73 This series of events leads to a phenotype whereby CaP cells have
less restriction on cell cycle progression, thereby promoting unregulated cell division.
Supporting these observations are other studies which show that as CaP progresses from an
androgen-dependent to -independent state, p27Kip1 levels are drastically diminished.74,75
Akt regulates the apoptotic response to a variety of stimuli via its ability to interact with a
number of key players in the apoptotic process. First, Akt can directly phosphorylate BAD on
S136,76 causing its inactivation and inability to interact with anti-apoptotic members of the
Bcl-2 family of proteins (Bcl-2, Bcl-XL).77 Next, activated Akt can independently inhibit the
release of cytochrome c from the mitochondria, which is a potent activator of the apoptotic
caspase cascade.65 Akt also is capable of phosphorylating procaspase-9, preventing its
cleavage into the pro-apoptotic caspase-9 initiator of programmed cell death.51 Lastly, the Akt
target, FKHR is capable of upregulating Fas ligand and Bim, two very important molecules
that are potent inducers of apoptosis; however, when inactivated by Akt, FKHR is localized to
the cytosol where it is unable to augment expression of these genes.49,79 Akt can also
phosphorylate Bim which inhibits its proapoptotic activity. In concert, these events caused by
Akt activation would appear to greatly affect the survival status of the cell.
Akt also plays significant roles in protein translation, particularly by regulating those proteins
involved in growth and survival. A specific target is mTOR (mammalian target of rapamycin)
which is able to induce phosphorylation of eIF-4E binding protein-1 (4E-BP1). After the
appropriate phosphorylation events, 4E-BP1 disassociates from the mRNA cap-binding
protein eIF-4E, which allows eIF-4E to interact with the eIF-4E translation initiation complex
to initiate protein synthesis. Another target of Akt is p70S6K which is a well-known enhancer
of protein synthesis.80-84 mTOR has been shown to be critically important in autophagy,
85-87 a mechanism of cell death which will be discussed below.
Messenger RNAs differ in their ability to be translated; the length and sequence of the 5' UTR
largely dictates the efficiency with which an mRNA transcript will be translated. Most mRNAs
contain short, unstructured GC-poor 5' UTRs and are efficiently translated. In contrast,
protooncogene and growth factor mRNAs are characterized by long, GC-rich sequences in the
5' UTR, which can often hinder the ability of the eIF-4E complex to efficiently scan and initiate
translation at the start codon. Consequently, under normal circumstances these mRNAs are not
efficiently translated.88,89 However, upon Akt-mediated activation of mTOR, these latter
mRNAs are highly and disproportionately translated; several key proteins that are
overexpressed as a consequence of this event include c-myc,90-96 cyclin D1,97,98 and
VEGF99 among others.88,89 Cyclin D1 has been reported to be overexpressed in CaP
xenografts and metastases,100,101 while early stage prostatic lesions possess much lower
levels of the protein.102 A number of reports support the notion that mTOR signaling is a
prominent feature of CaP progression, as recurrent tumors have altered expression of a number
of molecular targets of rapamycin.103-107 Hence mTOR inhibitors such as rapamycin may
be effective in prostate cancer therapy.
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Role of MAPK Signaling in Prostate Cancer
The PI3K/Akt signaling cascade is primarily associated with cell survival; conversely, the Raf/
MEK/ERK pathway is associated with growth, proliferation and differentiation.108-114
Despite the wealth of information surrounding the role of PI3K-mediated signaling in prostate
cancer, much less is known about the function of Raf/MEK/ERK signaling in CaP.
Like PI3K, activation of the Raf/MEK/ERK pathway is initiated by a mitogen-receptor ligation
at the cellular surface. Growth factor receptors are comprised of at least two subunits which
oligomerize upon binding of the respective mitogen; this event is immediately preceded by
increased tyrosine kinase activity on the cytoplasmic portion of the receptor. Most often this
is due to autophosphorylation, whereby one subunit of the receptor acts as a tyrosine kinase
and another subunit serves as a substrate. The phosphorylated tyrosine residue(s) then serve
as docking sites for cytoplasmic proteins that contain SH2 domains.115 After this event, a
complex of proteins is able to initiate a series of phospho-relay events that can ultimately alter
gene expression in the nucleus, as described hereafter.
Ras is a 21-kDa membrane-localized, monomeric G-protein that is considered to be the initiator
of signaling in the Raf/MEK/ERK pathway. The consensus amongst researchers is that
mutations in the Ras gene are relatively uncommon in prostatic malignancies116-118 as
compared to other tumor types (~30%). After receptor ligation and activation, SH2-containing
proteins are targeted to the phosphorylated tyrosine residue(s) on the receptor; one such protein
is Grb2.119 Grb2 also contains an SH3 domain whose primary function is to bind to proline-
rich regions of other molecules, such as SOS (Son of Sevenless). SOS is a guanine dissociation
stimulator of Ras which binds to Ras after receptor activation. After binding to SOS, Ras
undergoes a conformational change that causes the dissociation of GDP from Ras, allowing it
to then associate with GTP. In the GTP-bound form, Ras is in its active state and able to recruit
the Raf kinase to the plasma membrane for activation.120-123 To negatively regulate this
process, there exist a number of GTPase-activating proteins (GAPs) that are able to stimulate
the GTPase activity of Ras in order to convert it back to its original GDP-bound state.124
Immediately downstream of Ras is the Raf kinase. Currently, there are three known isoforms
of Raf: Raf-1 (c-Raf), A-Raf and B-Raf.125-128 Each of these isoforms has been described to
have both overlapping and unique regulatory functions.128 Activation of Raf (A-Raf and Raf-1
but not B-Raf) is a two-step process—first, active GTP-bound Ras recruits Raf to the cellular
membrane, which allows association with additional proteins necessary for activation (i.e.,
scaffolding proteins, etc.,).129 The first step is necessary but not sufficient for activation of
Raf. Consequently, a second step is required whereby Raf (A-Raf and Raf-1 but not B-Raf) is
phosphorylated on tyrosine and/or serine/ threonine residues. A member of the Src family of
kinases is responsible for this event when it occurs on tyrosine residues,130 whereas protein
kinase C (PKC) is a kinase implicated in activating Raf on serine/threonine residues.131,132
An overview of the Raf/MEK/ERK pathway is presented in Figure 2.
Regulation of Raf activation, however, is much more complex than simple phosphorylation of
a few nominal residues. Dr. Walter Kolch has contributed significantly to this area and has
published a number of thorough reviews on the topic.133-136 Briefly, Raf-1 is maintained in
an inactive state when phosphorylated on serines 259 and 621 by binding to 14-3-3 proteins.
136-138 Activation of Raf-1 is initialized when Ras displaces the 14-3-3 protein, allowing
phosphatase 2A (PP2A) to access and remove the phosphate group from S259.139,140
Evidence suggests that nearly 80% of all Raf-1 exists in the phospho-S259 form and that it is
impossible to activate the protein while in this state.138,141 When activated, Raf-1 is
phosphorylated on S338; mutation of this residue is sufficient to eradicate Raf-1 activation by
mitogenic stimulation.142,143 For these reasons, the use of phosphospecific antibodies to
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detect Raf-1 when phosphorylated on S338 has been used extensively as a qualitative indicator
of Raf-1 activity with reliable accuracy.143
After activation, Raf targets its downstream substrate(s) MEK1/2. MEK-1 and MEK-2
(hereafter, MEK) are phosphorylated on S218 and S222 by the Raf proteins.144
Phosphorylation on these two residues has been reported to increase MEK activity over 7000-
fold.145 The kinase suppressor of Ras (KSR) is a scaffolding protein that mediates the
interaction between Raf and MEK, allowing for efficient phosphorylation of the MEK protein.
146 Recent reports have suggested that the association of Raf, MEK and KSR is not as
simplistic as it was once thought—there appear to be modulators of KSR activity, including
MEK partner-1 (MP1)147 and Raf kinase inhibitor protein (RKIP).148 The function of MP1
is believed to be another scaffolding protein that enhances the association of MEK and B-Raf,
whereas RKIP actually disrupts the binding between Raf-1, MEK and RKIP. Together, each
of these proteins plays a unique role in the activation of MEK by Raf although it appears that
the molecules involved may be more numerous than just these proteins.133 RKIP has been
postulated to be a tumor suppressor protein. Relatedly, decreased expression of RKIP has been
associated with prostate cancer progression.148-150
ERK-1 and -2 are 44 and 42 kDa kinases that are directly downstream of the MEKs.
Phosphorylation of ERK-2 occurs on residues T183 and Y185; maximal activation is achieved
via phosphorylation by MEK on both of these residues.151,152 After activation, ERK-2 can
dimerize with other ERK-2 molecules and induce nuclear translocation.153 Upon entering the
nucleus, ERK-2 dimers are thought to activate an array of nuclear targets, including
topoisomerase II-α, suggesting that ERK-2 has a role in chromatin remodeling during mitotic
events.154 A number of cytoplasmic ERK targets exist as well, the primary of which is the
p90 ribosomal S6 kinase (p90RSK)155 which is responsible for phosphorylating several
transcriptional regulators including CREB,156 estrogen receptor-α157 IκB/NFκB,158,159 and
c-Fos.160 In addition to p90RSK, ERK is also a known inducer of the activator protein-1 (AP-1)
family of transcription factors; these modulators of transcription include c-Jun, c-Fos and
ATF-1 and each alters gene expression of individual target genes when activated. Each of the
above described phosphorylation promotes an environment that favors proliferation.
MAPK signal transduction has not been extensively studied in the prostate; very few
publications exist detailing the involvement of the Raf/MEK/ERK pathway in the advancement
of prostatic disease. Within the data that have been reported, there exists some degree of
divergence—some reports show that this cascade is involved in CaP development, while others
report the opposite. Consequently, the current level of understanding of MAPK activation in
CaP is ambiguous.
While aberrant MAPK activity is common in many cancers, there is little evidence to suggest
that MAPK activity is increased in CaP. The absence of mutations in Ras may be a factor that
contributes to this observation,117,118 as many cancers with constitutive MAPK activity
possess mutations in the Ras G-protein. One study has reported that activation of the MAPK
pathway with conditionallyactivated mutants of Raf resulted in cell cycle arrest and decreased
plating efficiency.161 Moreover, the authors suggested that activation of this pathway may be
a therapeutic target for CaP cells. Supporting this notion are other studies that show that
treatment of CaP cells with resveratrol or phenylethyl isothiocyanate, two compounds that
induce apoptosis in a variety of cancers, can induce apoptosis in cells of prostatic origin in an
ERK-dependent manner.162-164
The use of ERK activation as a prognostic indicator of disease is quickly becoming a useful
tool in determining the stage of progression of CaP. Initially, it was reported that ERK
activation was increased in high-grade PIN when compared to tissue derived from the normal
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prostate, as measured by immunohistochemical analysis.165,166 Another study supports this
observation; Price et al., show that there was significantly increased activation of ERK in tissue
removed from patients who had undergone radical prostatectomies.167 Contrary to these
results, however, are other reports which state that ERK activation is actually diminished as
the disease progresses from normal tissue to PIN to invasive carcinoma.168,169 Taken
together, these data are non-conclusive, but they do suggest that ERK activity may be a viable
means of determining patient prognosis if accurately ascertained. ERK activity may be
increased in certain subsets of prostate cancer patients.
Roles of Cell Cycle Proteins in Prostate Cancer
In addition to the PI3K/PTEN/Akt and Raf/MEK/ERK and other signaling pathways, lies a
complex network of proteins which regulate cell cycle progression. Often some of these cell
cycle regulatory proteins (e.g., p53) may serve to regulate the activity of signaling pathways
including PI3K/PTEN/Akt and Raf/MEK/ERK.170-181 An overview of some of these
potential interactions is presented in Figure 3. Numerous proteins involved in cell cycle
regulation are often mutated in prostate cancer, resulting in activation of oncogenes and loss
of tumor suppressor proteins. There is no dominant molecular profile that initiates or maintains
prostatic carcinogenesis, but rather a complex mixture of mutations that disrupt cell cycle
control and cell death pathways. Cell cycle proteins commonly mutated at early to late stages
of prostate cancer progression include Rb, p14, p16, p53 and p27.182-189 Mutations within
these proteins result in defective cell cycle checkpoint control, leading to further chromosomal
instability and inactivation of the protective tumor preventative failsafe, cellular senescence.
190-193 The PI3K/PTEN/Akt and Raf/MEK/ERK pathways are also commonly the target of
mutations that promote cell proliferation and block apoptosis and elicit some of their effects
through cell cycle pathways. Furthermore, and perhaps more importantly mutations at upstream
receptor genes feed into these pathways. Combined mutations within and among these
pathways may alter the success of radio- and chemotherapies. Knowledge of the pathways
altered, prior to initiating therapy, could provide a molecular signature for clinicians to optimize
sensitization strategies based upon the individual's profile. The use of small-molecule inhibitors
aimed at dysregulated pathways in combination with various therapeutic approaches may
improve the success of treatment and prolong survival of the patient.194-203
Although the frequency of p53 mutations in early prostate cancer is low, heterozygous loss of
function (LOF) mutations often accompany late stage carcinoma.189,204 Current models of
the molecular network coordinating responses to DNA damage place p53 at the crossroads of
several stress response pathways critical for maintaining genome integrity; including cell cycle
arrest, DNA repair, mitotic catastrophe, apoptosis and cellular senescence.205-211 The
mechanisms by which p53 directs cells down each of these alternative avenues of cell fate
determination differs among cells of various origins.212-214 It is important that each of these
distinct forms of p53-dependent cell death be collectively evaluated when investigating new
therapeutic strategies for increasing the sensitivity of CaP cells to various therapeutic
approaches.
Since p53 function is crucial to coordinating the DNA damage response, multiple upstream
pathways control p53 activation. While the list of stress signals that activate p53 continues to
grow, including hypoxia, ribosomal stress and loss of cell-cell contacts, the primary pathways
appear to be oncogenic stress and DNA damage. Interestingly, various stress signals use
different mechanisms for p53 activation. Under resting conditions, the ubiquitin degradation
pathway maintains a high rate of p53 turnover that is dependent on the E3 ubiquitin ligase,
murine double-minute 2 (MDM2).215-218 Hypophosphorylated MDM2 binds the p53 C-
terminus and targets p53 for degradation.219 Moreover, the p53 binding domain of MDM2
overlaps with the DNA binding domain of p53, effectively impairing p53 activity.220 The p53
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protein is also regulated by MDMX, a homologue of MDM2, that binds MDM2 through its C-
terminal RING domain and stimulates the MDM2-dependent ubiqutination of p53.215,221,
222 Therapy induced DNA damage triggers a phosphorylation cascade involving ataxia
teleangetasia mutated (ATM) and ATM-related (ATR) proteins that prevent p53 degradation
through multiple phosphorylation events on MDM2, MDMX and p53.223-228
Active p53 functions as a transcriptional regulator within a complex network involving the
selective transactivation and transrepression of multiple genes involved in cell cycle control
and apoptosis. p53 functions as a tetrameric transcription factor. The hetero-oligomerization
between a heterozygous mutant allele and wild-type (WT) p53 proteins may be sufficient to
alter the function of p53 tetramers. The dominant negative (DN) actions of missense p53
mutations were first demonstrated in experiments with ectopic expression of WT and mutant
p53 proteins204,229 and more recently in thymocytes expressing p53 point mutations at single-
copy levels.230,231 Alternatively, mutant p53 alleles may impart a gain of function (GOF)
that could also impact tumor development and the progression of prostate cancer.230-233
p53 can activate the Raf/MEK/ERK pathway by the discoidin domain receptor-1 (DDR-1).
234-236 Furthermore, ERK can phosphorylate p53 which results in its stabilization.237 The
PI3K/PTEN/Akt pathway also serves to regulate p53 activity through Akt-mediated
phosphorylation of MDM-2 which enhances its activity and destabilizes p53.238 Furthermore,
there are reciprocal interactions between p53 and PTEN which serve to cross regulate each
other's expression.239-242 Thus targeting the p53, PI3K/PTEN/Akt/mTOR and Raf/MEK/
ERK pathway may enhance certain prostate cancer therapies.
Many studies of in vitro prostate cancer sensitivity have used apoptosis assays to assess the
efficacy of cell killing and have been limited to a few CaP cell lines that were derived from
metastatic lesions containing p53 mutations rarely observed in organ-confined tumors.233,
243-245 The best characterized lines include PC-3 and DU145 cells that harbor pairs of deleted
or inactivated p53 alleles and display a complete loss of p53 function, a condition often
associated with decreased radiosensitivity.246-248 However, in cultures of CaP cells retaining
a functional p53 protein (LNCaP and 22Rv1) cellular senescence is the dominant form of death.
Alternative stress response pathways controlled by this tumor suppressor, including cell cycle
arrest, DNA damage repair, mitotic catastrophe and apoptosis, contributed significantly less
to radiation-induced death.249 Although autophagy is an additional form of cell death that has
recently been reported to enhance the therapeutic sensitivity of PC-3 and DU145 cells,249
neither of these cell lines express a functional p53. Thus, in the contemporary setting of earlier
detection where complete p53 inactivation is rare, the induction of terminal growth arrest may
be a primary mode of clonogenic death in radiation therapy of prostate cancer.250 This would
be consistent with the observation that in some patients complete regression of prostatic tumors
can take more than a year after finishing therapy.
Recent evidence indicates that tumor regression after therapy might involve the phagocytosis
of senescent cells by macrophages and the autophagy of senescent cells themselves.
Pronounced alterations in the endosomal/lysosomal pathway are evident in senescent cells.
Lipofuscin accumulation at the level of autophagic vacuoles accounts for the increased
granularity observed in the side-scatter profile of senescent cells and is a hallmark of cellular
senescence. Autophagy is an ancient pathway for homeostatic turnover of long-lived
intracellular components and for nutrient acquisition during starvation and stress. Recently,
p53 has been shown to positively modulate damage-regulated autophagy modulator (DRAM)-
dependent autophagy.251 Thus, therapy induced activation of p53, cellular senescence and
autophagy may contribute to the tumor regression observed in vivo when investigators have
experimentally “turned on” the p53 gene in tumor-bearing mice.252,253
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The p53, p21 and Rb tumor suppressors are important senescence regulators. p53, p21 and Rb
are transiently activated in response to stressors that induce ‘premature’ senescence in tumor
cells. Transactivation of the cyclin-dependent kinase (CDK) inhibitor p21 appears most
relevant as a downstream mediator of p53-dependent terminal growth arrest.254 How p21 and
other CDK inhibitors (e.g., p16Ink4a) promote senescence is not precisely known, but one well-
studied mechanism for p21-induced senescence involves the activation of Rb. Rb family
members (Rb, p107, p130) are corepressors of the E2F transcription factors required for cell
proliferation. With an accumulation of CDK inhibitors and the onset of senescent arrest, Rb is
converted to an active hypophosphorylated form that stably interacts with, and sequesters, E2F
and other proteins that influence gene expression and promote cell cycle progression.255
Notably, the cellular levels of p53, p21 and active Rb do not remain elevated after the onset of
senescence, suggesting that molecular interactions required to initiate the senescent state may
be dispensable for its maintenance. For example, conditional expression of p53, p21 or p16
causes cellular senescence in many settings, and the cells remain in a senescent state after
promoter shutoff.256-258 Because expression of another CDK inhibitor, p16, rises as p21 goes
down, it has been suggested that p16 may be responsible for maintaining a stable growth arrest,
while others contend that both p53 and p16 function in the maintenance of growth arrest in
senescent cells.259
Another recent explanation for the permanence of cellular senescence is that p16 enables Rb
to establish heterochromatin changes that maintain E2F-responsive promoters in an
irreversibly silenced state and no longer dependent on the presence of p16 or Rb.255 These
unusual foci of heterochromatin are physically associated with tightly packed and trimethylated
histone proteins (e.g., H3K9) and the histone methyltransferase Suv39h1.260,261 Whether
these p16/Rb-initiated modifications of heterochromatin are truly irreversible remains to be
determined. Moreover, there is evidence that the premature senescence induced by
chemotherapeutic drugs and radiation in tumor cells can occur in the absence of p53, p21 as
well as p16, indicating that additional genes and pathways may also mediate damage-induced
senescence of tumor cells.262
Rb inactivation is common in prostate cancer and generally precedes somatic alterations
affecting the tumor suppressor genes p53 and PTEN.183,185,263 Interactions among these
three major tumor suppressor genes appear to directly influence tumor development in the
mouse prostate.264,265 For instance, conditional deletion of an Rb allele specifically in the
mouse prostate epithelium results in the development of focal hyperplasia but not
tumorgenesis,266 while acute inactivation of PTEN alone induces a p53-dependent cellular
senescence.264 In contrast, when combined with inactivation of the Rb family proteins (Rb/
p107/p130) or p53, a loss of PTEN either elicits an accelerated rate of tumor progression or
development of invasive adenocarcinoma in mice, respectively.264-266 These transgenic
studies establish that a p53-mediated senescence response restricts cell proliferation after loss
of PTEN in the mouse prostate in vivo and that a concomitant loss of either Rb or p53 is
sufficient to bypass this impediment to tumor growth.
Treatment of Prostate Cancer
The primary treatment strategy for non-metastatic CaP is generally either radiation or complete
removal of the prostate (radical prostatectomy). Unfortunately, patients often relapse and
aberrant growth of the prostate returns (or the neoplasia is not detected in its infantile stages).
These patients are most often subjected to androgen ablation therapy in which either chemical
or surgical castration is performed in concert with non-steroidal anti-androgens. Furthermore,
since prostate cells are heavily reliant upon androgens for growth and/or survival, these cells
generally die within a short period of time. Consequently, the prostatic tumor undergoes a
complete remission for a period of approximately 18 months267
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After androgen ablation therapy, most tumors eventually relapse and begin to grow in the
absence of testosterone; this event is known as hormone relapse and patients in this stage are
said to possess hormone-refractory prostate cancer (HRPC). The expected lifespan of patients
who progress to the point of HRPC is less than 24 months and the prognosis is invariably death.
267 Hormone relapse is almost always accompanied by an increase in prostate-specific antigen
(PSA) levels. It is for this reason that measurement of PSA levels has become the primary
means of detection for tumorigenicity within the prostate.
After hormone relapse, therapeutic options become more limited. Modern chemotherapy is
just beginning to be commonly-utilized in the clinic. Until recently, it was believed that
chemotherapy was relatively ineffective against CaP cells,268,269 however, the development
of the PSA test as a qualitative measurement of therapeutic efficacy soon refuted the notion
that chemotherapy was ineffective in tumor cells of prostatic origin. Before the PSA test,
efficacy of chemotoxic drugs was primarily monitored by more objective means (tumor size
and/or volume), however it has now become evident that this method of assessing drug efficacy
is both inaccurate and unreliable—reported response rates from the same drug were increased
from 20% (tumor size) to nearly 75% (PSA levels) merely by changing the detection method
used in these studies.199 In light of these discoveries, there is a renewed interest in determining
the therapeutic value of chemo-therapy in CaP patients.
Most often, CaP patients are administered a variety of chemo-therapeutic compounds to combat
the disease.270-275 Employing the use of these drugs, however, has been met with only modest
success due to issues of toxicity and the drug-resistant nature of CaP. Efforts to minimize drug
resistance should prove effective in extending the life expectancy of HRPC patients.
Drug resistance is manifested via a multitude of biomolecular events including inhibiting
entrance of chemotoxic agents into the cell, loss of enzymatic activities involved in
metabolizing the drug, and overexpression of ABC (ATP-Binding Cassette) drug efflux pumps,
among others.276-278 Recently, we and others have shown that aberrant activity of the PI3K/
PTEN/Akt/mTOR signaling cascade can augment drug resistance in advanced CaP cells.279,
280 These reports detail several potential mechanisms responsible for increased
chemoresistance including PI3K-induced overexpression of the MRP-1 drug pump as well as
activation of the mTOR molecule that is downstream of PI3K/Akt. Consequently, targeted
inhibition of the PI3K/Akt signaling pathway is quickly gaining interest with regards to
chemotherapeutic intervention in an array of cell types281,282
Chemotherapy of Prostate Cancer
Chemotherapy agents used to combat CaP usually fall into three categories: (1) interchelating
agents (2) microtubule stabilizing agents, and (3) alkylating compounds. Anthracyclines are
antibiotic compounds derived from the Streptomyces species that are used to treat a variety of
cancers including CaP. Daunorubicin, doxorubicin and epirubicin are all members of this class
of compounds. Anthracyclines possess a number of mechanisms of action including
intercalating between base pairs of DNA, creating free radicals that initiate DNA damage, and
inhibition of the nuclear enzyme topoisomerase II.283 By intercalating into DNA,
anthracyclines inhibit both DNA and RNA synthesis.284,285 Inhibition of topoisomerase II,
which causes torsional strain on DNA causing strand breakage, was later proven to be an
integral event in anthracycline-induced cell death.286 Together, these modes of action initiate
a series of events that can ultimately lead to the demise of a cancer cell
Mitoxantrone is an anthracenedione with a structure similar to doxorubicin but appears to have
a better toxicity profile than that of anthracyclines.287,288 Due to its similar structure to
anthracyclines, it is not surprising that the mechanism of action of mitoxantrone is similar as
well. Mitoxantrone is thought to induce apoptosis by both DNA intercalation and inhibition of
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topoisomerase II activity.287,288 Mitoxantrone has been investigated for its ability to induce
death of CaP cells—these studies have concluded that mitoxantrone is effective in palliation
of CaP symptoms, but is unlikely to prolong survival.287,288
The central premise behind all neoplasia is the uncontrolled nature of cell division. An
accumulation of genetic events (i.e., mutations) that affect the cell cycle can lead to aberrant
growth and cell division. Therefore, the process of mitosis whereby the mitotic spindle
functions to divide chromatids to each daughter cell is a viable target in many cancers.
Microtubules comprise the mitotic spindle and proper polymerization/depolymerization of
these microtubules is essential for efficient progression through mitosis and subsequent cell
division. Taxanes are a family of chemotherapeutic drugs that have the capacity to bind to
microtubules, specifically β-tubulin, thereby preventing depolymerization.289,290 This event
is essential for cell division; as such, the use of taxanes has become prominent in cancer
research, particularly CaP.291-293 There are a growing number of taxanes currently available
in the clinic including paclitaxel and docetaxel. Interestingly, these drugs may have an
additional modes of action: they appear to induce the phosphorylation and inactivation of the
anti-apoptotic molecule, Bcl-2.294,295
Estramustine is a stable conjugate of estradiol and nornitrogen mustard296 that is commonly
used in CaP patients. Estramustine was designed as an alkylating agent specifically for
treatment in tumors of prostatic origin. The premise of the initial design of the drug was that
the estradiol portion of the agent would facilitate uptake by steroid receptors, whereas the
nitrogen mustard moiety would perform the alkylation; however, evidence exists to refute the
notion that estramustine acts in this manner. It is thought that estramustine inhibits microtubule
function and affects structural proteins within the nuclear matrix.297,298 In high doses,
estramustine is not well-tolerated,299 however it is currently being evaluated in combination
with other drugs at less toxic doses and results have been promising.
Roles of PI3K/PTEN/Akt/mTOR, Raf/MEK/ERK and p53 Pathways in Prostate
Cancer Drug Resistance
The PI3K/PTEN/Akt/mTOR signal transduction pathway is well-known for its roles in cell
cycle progression, survival and growth of cells. Recent evidence suggests that this pathway
may also contribute to the development of drug resistance in a variety of cell types.300-308
Efforts to identify specific molecules that confer drug resistance will be the next wave of these
types of studies. To this point, the data disproportionately implicates the PI3K/PTEN/Akt/
mTOR pathway in the development of drug resistance. However, this pathway is capable of
inducing such effects in a number of ways; as such, it is necessary to investigate potential
means of resistance in these cell types.
Given the involvement of ABC drug transporters in acquired chemoresistance, we monitored
the expression of prototypical members of the ABC superfamily of efflux pumps.281 None of
the CaP cell lines tested (LNCaP, 22Rv-1, DU145 or PC3) was positive for MDR-1 gene
expression. Interestingly, CaP cells with constitutive PI3K activity were positive for MRP-1
expression, whereas PTEN-positive (DU145 wild-type) cells expressed minimal levels of this
gene.281 However, activation of PI3K in DU145 cells potentiated upregulation of MRP-1,
indicating that the PI3K pathway may modulate expression of the MRP-1 gene. The
observations made on the RNA level were congruent with those reported in a recent publication
where the authors showed that MRP-1, not MDR-1, was the predominant drug pump expressed
in advanced CaP cells.281 These trends were also observed on the protein level when various
DN PTEN and constitutively-active PI3K mutants were observed to increase levels of the
MRP-1 gene product.281 Collectively, the data identify MRP-1 as a mediator of CaP drug
resistance and an indirect mechanism responsible for its upregulation.
Lee et al. Page 11
Cell Cycle. Author manuscript; available in PMC 2008 December 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Wang and Beck were the first to hypothesize that p53 is a negative regulator of MRP-1
expression.309 However, to date, there is no report of any p53-binding motifs located within
the MRP-1 promoter region.310 Therefore, one might hypothesize that repression of MRP-1
by p53 occurs by an indirect means rather than an immediate interaction with the MRP-1
promoter. Beck also reported that expression of the specificity protein-1 (Sp1) transcription
factor is a strong activator of MRP-1 expression.309 Given that there are three Sp1 binding
sites in the MRP-1 promoter and that Sp1 activity has been reported to be PI3K-dependent,
310 it is plausible to suggest that Sp1 is critical for MRP-1 expression in advanced CaP cells.
p53 (LNCaP: p53-positive, DU145 and PC3: p53-negative) may be the dominant regulatory
molecule governing MRP-1 expression, but PI3K activity and subsequent Sp1 activation, may
be necessary for maximal expression of MRP-1.
To assess the role of MRP-1 in mediating chemoresistance in DU145 and PC3 cells, RNA
interference was exploited to inhibit expression of this gene. The results presented in Lee et
al., prove that inhibition of MRP-1 function, through downregulation of MRP-1 expression,
can sensitize MRP-1-expressing cells to chemo-therapeutic compounds.281 The importance
of these findings is significant because it provides a viable target for future antineo-plastic drug
formulations—agents synthesized to antagonize the activity of MRP-1 should increase the
efficacy of chemotoxic drugs while having minor, if any, effects on the viability of cells not
expressing MRP-1.
Lastly, it is imperative to consider the context of PI3K signaling in CaP cells. The PI3K/PTEN/
Akt/mTOR pathway is most often accepted as a mediator of cellular survival, rather than
proliferation (i.e., MAPK signaling). Within the prostate gland, the population of cells that
undergo active proliferation is between 1-3%311,312 and this observation may explain why
diagnosis of CaP does not often occur before the latter stages of life. Although proliferation of
CaP cells is slow, turnover of CaP cells appears to be slower—the loss of PTEN and
upregulation of PI3K activity leads to a pheno-type whereby the cell does not undergo apoptosis
when directed. Consequently, pathways that mediate survival, rather than proliferation (i.e.,
Raf/MEK/ERK signaling), may be more attractive targets for reducing tumor growth in CaP
patients.
MAPK Signaling and Drug Resistance Studies
The Raf/MEK/ERK signal transduction cascade is responsible for a number of cellular
processes including proliferation, growth and differentiation. The relationship between Raf/
MEK/ERK signaling and drug resistance is also well-documented. There are reports which
propose that activation of the Raf/MEK/ERK pathway can increase the probability of survival
in chemotoxic agents;313,314 conversely, there is also an abundance of data which suggests
that activation of ERK is a necessity for drug-induced apoptosis.315-319 In prostatic disease,
however, the role of ERK activation in chemoresistance remains controversial. At this time,
there does not appear to be a single role for ERK in drug-induced cell death—instead, it seems
that cell type and drug selection are two key factors in evaluating the role of ERK activation
to drug treatments.
To examine the effects of ERK activity on the development of drug resistance in CaP cells,
DU145 cells were stably-transfected with constitutively-activated mutants of both Raf-1
(ΔRaf-1) and BRaf (B-Raf G468A and B-Raf V600E).320 In doing so, it was possible to
ascertain the role(s) of Raf/MEK/ERK activation in altering the response of CaP cells to
doxorubicin or paclitaxel treatment. Each of the constitutively-active mutants was able to
increase activity of ERK, as measured by a phospho-specific antibody. Thus, it was then
possible to move forward with these studies with the knowledge that the cell lines had increased
activity of the Raf/MEK/ERK pathway when compared to non-transduced DU145 cells.
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The effects of activation of the Raf kinase, via stable transfection of various DNA constructs,
were then determined. The data,320 were somewhat surprising because they showed that
activation of the Raf/MEK/ERK pathway did not enhance the chemoresistance profile of
DU145 cells. On the contrary, subsequent experiments have indicated that activation of this
cascade upon restoration of WT p53, increased the sensitivity of the cells to both radiotherapy
and chemotherapy.250
To confirm/refute the intriguing results, further experiments were performed. Those data
demonstrate that inhibition of MAPK activity does little to enhance the killing capacity of
doxorubicin and/or paclitaxel in DU145 cells. Together, these data confirm the data from
previous studies and strongly suggest that activation of the Raf/MEK/ERK signaling cascade
does not increase drug resistance in CaP cells. In fact activation of Raf/MEK/ERK may actually
chemosensitize prostate cancer cells.
Initially, these results were somewhat surprising because our and other laboratories have
previously reported321-323 that activation of the Raf/MEK/ERK cascade provided protection
from doxorubicin in the MCF-7 breast carcinoma and other cell lines. However, after a
thorough literature search, it appears that activation of the Raf/MEK/ERK pathway has a pro-
apoptotic effect when cancer cells are treated with chemotherapeutic agents in the majority of
cell types. Interestingly, the pro-apoptotic action of drug-induced ERK activity is reported to
be p53-dependent.324,325 DU145 cells, however, possess a mutated p53 protein product
which is insufficient in many of the activities associated with WT p53 activity (i.e., DNA
damage-induced cell cycle arrest and p21 regulation, among others).326 Therefore, it is quite
feasible that activation of the Raf/MEK/ERK pathway is unable to induce chemoresistance in
DU145 cells because of the absence of WT p53 function in this cell type. When a functional
p53 gene was introduced into these cells, their chemo- and radiosensitivity increased
dramatically as did the activation of the Raf/MEK/ERK cascade.
Intracellular signaling does not occur in a linear fashion. Instead, signaling between adjacent
pathways is known to converge, cross and intersect one another in a complex, interwoven
pattern that is generally undefined. Oftentimes, reports on crosstalk between pathways conflict
each other, indicating that cell type must be considered when determining potential interactions
within the cell. There are very few reports that have investigated the degree of crosstalk that
occurs in cells of prostatic origin. Given the importance of the topic of these studies, it was
vital to determine if potential crosstalk between the PI3K/PTEN/Akt and Raf/MEK/ERK
pathways occurs and, if so, to what degree it affects drug resistance in CaP cells.
Dr. Jeffrey Kreisberg's laboratory (University of Texas Health Science Center, San Antonio)
has demonstrated the importance of monitoring phospho-Akt levels as a prognostic tool for
CaP patients.327,328 In addition, they also report that decreased phospho-ERK levels are
indicative of a poor prognosis.327 Taken as a collective whole, the correlative data might
suggest that activation of Akt is linked to the inactivation of ERK. This hypothesis was
investigated further because preliminary data indicated that it may indeed be true.
It was soon discovered that inhibition of PI3K with LY294002 could cause increased levels of
phospho-ERK.329 This finding was subsequently verified using another inhibitor of PI3K,
wortmannin. These results suggested that activated PI3K could mediate downregulation of the
Raf/MEK/ERK pathway when active; on the contrary, inhibition of PI3K appears to activate
the MAPK pathway.329
The complex phosphoregulation of Raf was described earlier; it is generally accepted that
phosphorylation of S259 on Raf-1 is an event that inactivates the molecule from signaling
downstream (to MEK).330 To assess Raf activity in CaP cells, both DU145 and PC3 cells were
assayed for their phospho-Raf-1S259 content. Interestingly, PC3 cells displayed much higher
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levels of inactivated Raf-1 than the DU145 cell line.329 This observation supports the
hypothesis that activated PI3K/Akt can suppress the Raf/MEK/ERK pathway in a manner that
involves Raf-1 inactivation.
To further test the hypothesis that the PI3K/Akt pathway causes inactivation of ERK through
phosphorylation of Raf-1, reciprocal co-immunoprecipitation assays demonstrated that Akt
and Raf-1 were found in conjunction with one another in PC3 cells; however, this was not as
apparent in the DU145 cell type.329 DU145 and PC3 cells were also subjected to low
concentrations of doxorubicin and/or paclitaxel over two months and resistant cells were
selected. DU145 cells selected in drug displayed elevated high levels of phospho-ERK, but
relative levels of phospho-Akt when compared to wild-type cells.329 PC3 cells, however, were
unchanged in terms of phospho-Akt (high levels) and phospho-ERK (low). Together, these
analyses support the notion that the absence of PTEN plays a major role in the inactivation of
Raf-1 in PC3 cells, but not DU145 cells. While the evidence presented to prove that activation
of ERK to potentiate the anti-apoptotic effects of doxorubicin and paclitaxel is minimal, the
literature certainly supports this premise.318,319,330-333 Consequently, it appears that PI3K
activation may have an additional mechanism of action to confer drug resistance to CaP cells
—inactivation of the Raf/MEK/ERK kinase cascade.
The significance of the studies performed is several-fold and has implications for not only
acquired chemoresistance, but also normal progression of prostatic disease. The loss of
PTEN expression appears to be a major factor in a series of events that can lead to drug-
resistance and HRPC. After PTEN-loss and consequent activation of PI3K, resistance to
chemotherapeutic compounds can occur in a number of ways. First, activation of PI3K was
shown to upregulate expression of the MRP-1 drug efflux pump gene through an unknown
mechanism. Secondly, PI3K can activate Akt which can deactivate Raf by phosphorylation on
S259; inactivation of Raf shuts down Raf/MEK/ERK signaling, which has been shown to be
essential for chemotoxic drug-induced death. Although there exist alternative mechanisms
which the CaP cell employs to become resistant to antineoplastic agents, steps can be taken
now to exploit this new knowledge so that better therapies are present in the future.
Activation of Raf-1 and/or B-Raf was not capable of increasing the cellular resistance to either
doxorubicin and/or paclitaxel. Initially, this was a troublesome finding because most believe
that Raf/MEK/ERK activation leads to an intracellular state that enables the cell to more
effectively respond to chemotoxic compounds. However, upon further analysis, it was
discovered that this mechanism of action is dependent on the activity of the tumor suppressor
protein, p53. Pertinent to these studies is that DU145 cells are p53 mutants (PC3: p53-null).
Taken together, this data helps explain why activation of Raf-1 and B-Raf is insufficient to
sensitize DU145 cells to doxorubicin and/or paclitaxel. Therefore, chemotherapeutic resistance
proves to be a complex process depending on activates of multiple signaling pathways.
Radiosesitization of Prostate Cancer
Conventional-dose (72 Gy) external beam radiation is elected as a preferred treatment modality
by many CaP patients.334,335 However, there is evidence that conventional-dose radiation
often does not provide complete tumor eradication with a resultant radiorecur-rent prostate
cancer and five year distant metastasis-free survival of less than 80%.336-338 Given this
problem, it is not surprising that radiotherapy dose escalation has been recommended for
patients with poor prognostic features (e.g., positive surgical margins);339 but the toxicity
associated with dose-escalated therapy is not trivial and it is recognized that 5-10% of all
radiotherapy patients develop severe acute or late effects.247 Accordingly, there is intense
interest in understanding critical determinants in the efficacy of irradiation (IR)-induced CaP
cell killing and developing targeted therapeutic strategies for radiosensitization.
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Curative radiation therapy aims at preventing tumor regrowth by inducing tumor cell death
and loss of reproductive integrity. These processes together are referred to as clonogenic death.
Clonogenic cells are defined as tumor cells possessing the capacity to produce a colony of
progeny and therefore contribute to the regrowth of the tumor. These cells are also more
commonly referred to in other types of cancer as tumor stem cells or cancer-initiating cells.
340-346
Radiation therapy creates substantial DNA damage that is recognized by p53 and forces most
cells to either undergo programmed cell death (e.g., apoptosis), necrosis or enter a state of
reproductive death (i.e., cellular senescence). Radiation therapy is conventionally delivered in
fractions of 1.8-2.0 Gy doses for 5 days a week until a total of 60-80 Gy is reached. After
sequential doses, more than 99% of the malignant cells are typically killed. However, the
surviving fraction may amount to more than a million cells per gram of tumor volume.347
These survivors retain the potential to actively contribute to radiorecurrent prostate cancer and
are a major target for radiosensitization. However, the cellular and molecular heterogeneity of
CaP make this subpopulation of radioresistant cells a difficult target to strike using a single
modality of adjunctive therapy.349
Priming the p53 Pathway for Prostate Cancer Therapy
p53 activity is regulated by the E3 ubiquitin ligase MDM2, which binds and targets p53 for
degradation.350 Overexpression of MDM2 has been reported in prostate cancer cells and may
serve to protect those cells from p53-mediated cellular senescence in response to therapy.
350 Thus, targeting MDM2 seems to be a reasonable target for sensitization to both
chemotherapy and radiotherapy. Investigators have downregulated MDM2 using antisense and
successfully sensitized LNCaP cells.351,352 While antisense raised against MDM2
demonstrated that regulation of p53 is critical for sensitization, the use of antisense may prove
to be difficult in the clinical setting.
Recently, a selective small-molecule inhibitor of MDM2-p53 binding, Nutlin-3 has been
identified and characterized. Nutlin-3 disrupts MDM2 binding and p53 in cell culture at a
concentration of 5-10 μM or inhibits tumor growth when given orally at 200 mg/kg.353
Nutlin-3 specifically activated the p53 pathway in numerous cancer cells possessing WT p53,
inducing cell cycle arrest and apoptosis to varying extents.354 Since Nutlin-3 uncouples p53
from MDM2-mediated degradation, treatment with the drug prior to therapy may increase
steady-state levels of p53, effectively priming the cellular ability to respond maximally to
radiation. Investigators first demonstrated that administration of Nutlin-3 prior to therapy can
effectively sensitize WT p53 lung cancer cells.245 We have recently shown that disruption of
p53-MDM2 interactions by the small-molecule MDM2 antagonist Nutlin-3 can effectively
sensitize prostate cancer cells to a clinically-relevant dose (2 Gy) of IR, provided these CaP
cells express WT p53.250 Moreover, the increase in clonogenic cell death was entirely
attributable to an increased induction of p53-dependent cellular senescence.
While Nutlin-3 may radiosensitize some tumors by “priming” the p53 pathway, it seems clear
that this strategy will not apply to all prostate tumors. p53 activation requires both MDM2
degradation and MDMX inactivation. Nutlin-3 does not disrupt MDMX binding of MDM2
and MDMX overexpression prevents p53 stabilization by Nutlin-3.354 Nutlin-3 disrupts
MDM2 binding and inactivation of p53 in cell culture models. The observations suggest that
further development of small-molecule inhibitors of MDMX, or alternative molecular targets,
may be useful in combination with Nutlin-3 to provide a clinically effective radioresponse.
Moreover, p53 activators could have an adverse outcome in patients with p53 GOF mutant
alleles and it will be essential to determine their p53 status prior to initiating treatment.355
Because prostate cancer is slow growing and is now often detected while still localized, the
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clinician may some day have the opportunity to individualize treatment based on knowledge
of the patient's p53 status.
AKT as an Adjunctive Target to p53 in Sensitization of Prostate Cancer
Small molecule inhibitors of PI3K such as LY294002 have been reported to effectively
sensitize LNCaP and other prostate cancer cells.281,356 Recently the novel Akt inhibitor,
Perifosine, has been shown to have some effects on prostate cancer growth.357 Thus,
inactivating mutations of PTEN may limit therapy induced cell killing in prostate tumors due
to unrestrained Akt activity. This may be related to the observation that the PI3K-Akt pathway
effectively inhibits p53 by increasing its degradation via the MDM2 pathway.358 More
recently, however, it has been reported that activation of PI3K signaling results in the
downstream activation of p53 and the p53-dependent senescence pathway.359-361 This
discrepancy may be the result of oncogenic stress stimulating p14, which would inactivate
MDM2 regardless of the increased shuttling into the nucleus via Akt phosphorylation. Thus it
is unclear whether targeting the Akt pathway in conjunction with p53 activation will synergize
or antagonize the radioresponsiveness of prostate cancer cells. Future studies will be directed
at resolving this controversy in order to understand how and when these tumor suppressor
pathways interact to influence the radiosensitivity of CaP cells.
Conclusions
The developments of complimentary or alternative treatment strategies to standard chemo- and
radiotherapies are invaluable to increase survival in patients with metastatic CaP. After
hormone relapse, nearly 100% of patients succumb to this disease within 18 months. During
this period, chemotherapy is administered primarily for palliation of symptoms associated with
disease. Given the success of chemotherapeutic intervention in other cancer types, it stands to
reason that it can be an effective means of treatment for prostatic disease as well. However,
defining the mechanisms of chemoresistance within the prostatic tumor will be the caveat that
enables this notion to become a reality.
Studies that investigate the mechanistic behavior of androgen-independent CaP cells are of the
utmost importance in discovering better treatments with higher levels of efficacy. The genotype
of the tumor must be considered when developing treatment regimens for a CaP patient as
multiple signaling pathways feed into each other. Fortunately, it appears that clinical
oncologists are headed in this direction,361,362 as many physicians are beginning to push for
the development of diagnostic tools that can be utilized to determine specific mutations that
are present in a particular person's tumor. Taking into account the research discussed in this
review, it appears that genotyping tumors will be an effective means of developing better
treatment strategies for patients with HRPC, as the absence of a single gene (i.e., PTEN) can
make a substantial difference in the response of patients to chemotherapeutic agents. In Figure
4, an overview is presented of the sites of mutation which have been identified in prostate
cancer which result in activation of the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways.
In previous publications, we have reported that the PI3K/PTEN/Akt/mTOR and Raf/MEK/
ERK signaling pathways have synergistic effects which lead to the transformation of
hematopoietic cells.363-369 Recently, we reported that Akt activation can lead to inactivation
of the MAPK pathway via Raf-1.329 The results of these studies have importance in many
arenas of prostatic research: disease progression and etiology, therapeutic efficacy and
resistance to chemotoxic compounds.
PTEN, the negative regulator of PI3K signaling, is lost in a large percentage of prostatic
carcinomas. Consequently, many patients with CaP harbor tumors with high levels of Akt
signaling.370,371 Our previous work demonstrated that aberrant Akt signaling can lead to
Lee et al. Page 16
Cell Cycle. Author manuscript; available in PMC 2008 December 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
heightened levels of MRP-1 expression thereby causing increased resistance to doxorubicin
and paclitaxel, two drugs commonly used to treat CaP patients.281 Furthermore, we also
demonstrated the role for Akt in the progression of CaP, namely inactivation of the Raf/MEK/
ERK cascade.329
Signals transduced by the Raf/MEK/ERK cascade are generally thought to induce cellular
growth, differentiation and/or proliferation.372 Given that chemotoxic drugs target cells which
divide rapidly, one would then hypothesize that cells with high levels of ERK activity would
be more effectively targeted by these compounds. Conversely, the PI3K/Akt pathway is known
for its role in cell survival—as such, cells with heightened Akt activity may not be as affected
by treatment with chemotherapeutic drugs. Our previous reports281,363 support this
hypothesis.
Inactivation of ERK has been reported to coincide with higher Gleason grades and poorly
differentiated CaP.373 Due to its role in inducing differentiation, one hypothesis is that, in
normal prostatic epithelial cells, ERK acts to induce cellular differentiation; however upon
tumorigenesis, ERK is inactivated causing cells to differentiate much less efficiently, which is
a hallmark of advanced CaP.371 The data presented in our recent report support the notion that
ERK is inactivated in advanced CaP.329 Furthermore, evidence in this report329 indicates that
loss of PTEN and subsequent Akt activation is responsible for ERK inactivation via
phosphorylation of Raf-1 on S259.329 Lastly, others have shown that ERK activation is
necessary for drug-induced death;374-376 the findings herein suggest that administration of
chemotoxic drugs may have minor deleterious effects in cells with heightened Akt activity
(i.e., those with PTEN deletions), as they will serve to downregulate signaling within the Raf/
MEK/ERK pathway. Tumor suppressors such as p53, PTEN and Rb play critical roles in
prostate cancer growth. Clearly mutation at these tumor suppressors have multiple effects on
cellular growth and death pathways. A summary of the effects of PTEN and p53 inactivation
on PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK in prostate cancer is presented in Figure 5.
Resistance to chemotherapeutic compounds is a problem that continues to impede the success
of modern drug regimens.377,378 Circumventing this resistance is an area of intense
investigation due to the short life-span of patients who are afflicted with HRPC. Previously,
we and others have identified the PI3K/Akt pathway as a primary mediator of drug resistance
in advanced CaP.281,379 After loss or mutation of PTEN, Akt becomes constitutively active
thereby causing phosphorylation and inactivation of Raf-1 on S259.329 Since this event is one
that inactivates Raf-1, signals ordinarily transduced by the Raf/MEK/ERK cascade are negated.
Consequently, the cell loses its ability to further differentiate, while heightened Akt activity
confers a survival advantage to the cell. Together, these events may lead to a tumor
microenvironment where the individual cells are not only resistant to chemotherapeutic
compounds, but also fail to differentiate efficiently. While chemotherapeutics have had
minimal success so far, the future for effective treatment may involve combinations with drugs
simultaneously targeting signaling pathways (Akt, MAPK, p53). Clearly combining targeted
therapy with chemotherapy as well as other therapeutic approaches may have significant
potential in prostate cancer therapy as prostate cancer is a disease based in part on mutations
in critical signaling and cell cycle regulatory genes which aberrantly regulate prostate cell
growth.
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Figure 1.
Overview of PI3K/PTEN/Akt/mTOR Pathway. The PI3K/PTEN/Akt/mTOR pathway is
regulated by Ras as well as various kinases. The PI3K/PTEN/Akt/mTOR pathway is also
activated after receptor ligation. The PTEN phosphatase (black octagon) inhibits activation of
PI3K. Downstream of PI3K, Akt has many downstream targets that regulate cell growth and
apoptosis. The transcription factors regulated by these pathways are indicated in diamond-
shaped outlines. Dotted lines in front of AAA indicate that there is suppression of expression
of some genes due to Akt phosphorylation of transcription factors such as Foxo3. Some of the
interactions between the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways are also
indicated.
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Figure 2.
Overview of Raf/MEK/ERK Pathway. The Raf/MEK/ERK pathway is regulated by Ras as
well as various kinases (PKC, PAK, PKA). Many kinases serve to phosphorylate S/T and Y
residues on Raf. Some of these phosphorylation events serve to enhance Raf activity (black P
in a white circle) whereas others serve to inhibit Raf activity (white P in a black circle. Moreover
there are phosphatases such as PP2A, which remove phosphates on certain regulatory residues.
The downstream transcription factors regulated by this pathway are indicated in diamond-
shaped outlines. Raf can also exert effects which are independent of MEK/ERK and can interact
with mitochondrial proteins to regulate apoptosis.
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Figure 3.
Interactions Between PI3K/PTEN/Akt/mTOR, Raf/MEK/ERK and Cell Cycle Pathways in
Prostate Cancer. All of these pathways interact to regulate the induction of cell cycle
progression and apoptosis. The Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways
normally serve to suppress apoptosis while p53, which is induced by certain chemotherapeutic
drugs and ionizing radiation, will result in increases in pro-apoptotic family members and in
some cases, growth factors which may activate certain growth factor receptors. p53 can also
regulate the transcription of many genes including p21Cip-1, Bax, Puma, Noxa and other genes
which serve to regulate cell cycle progression and the induction of apoptosis. Furthermore, p53
activity can be altered by phosphorylation by ERK as well as MDM2 levels, whose activity is
in turn previously regulated by Akt. Hence these pathways are interconnected and serve to
regulate each other.
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Figure 4.
Sites of Mutation which can Result in Altered PI3K/PTEN/Akt/mTOR Raf/MEK/ERK and
Cell Cycle Pathways in Prostate Cells. Mutations and deletions have been detected in p53,
PTEN, Rb, AR and many other genes in prostate cancer. Many of these mutations and
chromosomal trans-locations result in activation or inactivation of the Raf/MEK/ERK, PI3K/
PTEN/Akt/mTOR cascades as well as pathways which control cell cycle progression and
apoptosis. The most frequently mutated genes are indicated by a starburst symbol.
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Figure 5.
Effects of PTEN and p53 Inactivation on PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK
Activation in Prostate Cancer. Some of the complex interactions between the PI3K/PTEN/
Akt/mTOR, Raf/MEK/ERK, p53 and cell cycle pathways and how they influence cell cycle
progression in prostate cancer are presented.
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